Veracyte to Participate in Morgan Stanley Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 /CourierPR/ -- Veracyte, a leading cancer diagnostics company, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The event, scheduled to begin at 7:00 a.m. Eastern Time, will feature an in-depth discussion on the company's innovative diagnostics solutions and their impact on cancer care.

The presentation will be live-streamed on Veracyte’s website, allowing attendees and investors to access the session remotely. After the live event, a recording will remain available for 90 days, ensuring that those who couldn't attend can still benefit from the insights provided.

Veracyte specializes in developing molecular tests that analyze the unique biology of patient tumors to aid in cancer care decisions. The company’s diagnostics platform integrates genomic and clinical data, advanced bioinformatics, and artificial intelligence to drive continued innovation and pipeline development. Its portfolio includes several key tests such as the Afirma® Genomic Sequencing Classifier, Decipher® Bladder Genomic Classifier, Decipher® Prostate Genomic Classifier, Prosigna® Breast Risk of Recurrence, and the TrueMRD™ Monitoring Test for MIBC.

By participating in this conference, Veracyte aims to share its latest advancements and strategies with industry leaders, investors, and healthcare professionals. The event marks a significant opportunity for the company to showcase its contributions to transforming cancer care globally.